CD274 and neoplasm: In conclusion, our findings suggest that HAIT combined with molecular targeted therapies and PD-(L)1 inhibitors may improve PFS and tumor response rates, and show a trend toward better OS compared to HAIT alone in patients with locally aggressive erHCC.